GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Cyclically Adjusted PB Ratio

Phio Pharmaceuticals (Phio Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.00 (As of May. 22, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-22), Phio Pharmaceuticals's current share price is $0.7599. Phio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $2,891.65. Phio Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Phio Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

PHIO's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.71
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Phio Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $1.220. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2,891.65 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Phio Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Phio Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 - - -

Phio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Phio Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Phio Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Phio Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Phio Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.7599/2891.65
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Phio Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.22/131.7762*131.7762
=1.220

Current CPI (Mar. 2024) = 131.7762.

Phio Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 10,068.182 100.560 13,193.649
201409 8,987.500 100.428 11,792.936
201412 3,536.364 99.070 4,703.846
201503 5,334.043 99.621 7,055.733
201506 13,398.980 100.684 17,536.733
201509 11,257.143 100.392 14,776.386
201512 8,979.798 99.792 11,857.853
201603 7,023.232 100.470 9,211.617
201606 5,018.182 101.688 6,502.993
201609 3,036.000 101.861 3,927.632
201612 3,720.812 101.863 4,813.484
201703 2,469.162 102.862 3,163.230
201706 1,686.648 103.349 2,150.576
201709 955.432 104.136 1,209.031
201712 498.098 104.011 631.062
201803 138.631 105.290 173.505
201806 495.008 106.317 613.546
201809 259.644 106.507 321.246
201812 475.587 105.998 591.248
201903 329.063 107.251 404.312
201906 255.313 108.070 311.320
201909 195.652 108.329 237.999
201912 103.029 108.420 125.224
202003 50.149 108.902 60.683
202006 36.815 108.767 44.603
202009 32.079 109.815 38.494
202012 27.020 109.897 32.399
202103 27.840 111.754 32.828
202106 25.575 114.631 29.400
202109 22.383 115.734 25.486
202112 19.445 117.630 21.784
202203 17.089 121.301 18.565
202206 14.938 125.017 15.746
202209 11.876 125.227 12.497
202212 9.515 125.222 10.013
202303 6.354 127.348 6.575
202306 4.989 128.729 5.107
202309 3.126 129.860 3.172
202312 2.063 129.419 2.101
202403 1.220 131.776 1.220

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Phio Pharmaceuticals  (NAS:PHIO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Phio Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (Phio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.
Executives
Robert J Bitterman director C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford director UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh director, officer: President and CEO 1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev officer: Chief Business Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman director 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc 10 percent owner 1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco officer: Chief Development Officer C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis officer: Secretary and Controller 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581

Phio Pharmaceuticals (Phio Pharmaceuticals) Headlines

From GuruFocus